Navigation Links
Positive Results Prompt US National Cancer Institute to Make,Gleevec Available To Patients in Post-Surgical Gist Study

ators on a submission to gain regulatory approval for Gleevec as adjuvant treatment for GIST."

Following the recommendation of a data monitoring committee, the study will be closed and patients in the study who are currently being treated with placebo may choose to receive one year of Gleevec.

In the study, patients were randomized to one of two treatment arms. Neither the patients nor physicians knew which treatment the patients were receiving. One patient group received Gleevec at a dose of 400 milligrams per day for one year, while the second group received placebo for one year. According to the study design, patients who developed a recurrence of their cancer while on a study therapy were unblinded to their treatment assignment. Those receiving placebo subsequently received Gleevec, while those already given Gleevec continued with this therapy but at a higher dose. Study results will be presented at a forthcoming scientific meeting.

Gastrointestinal stromal tumors (GIST) belong to a group of cancers known as soft tissue sarcomas that usually arise from the intestinal tract, with the most common site being the stomach followed by the small intestine. The incidence of GIST is estimated to be 4,500-6,000 new cases per year in the US (15-20 cases per million population), of which more than 90% are kit-positive.

Investigators in the NCI study reported that Gleevec therapy was well tolerated by most patients, with side effects similar to those observed in other clinical trials with Gleevec. These include nausea, diarrhea and swelling (edema). Information on more than 600 patients enrolled in the study was used in the analysis.

About Gleevec

Gleevec(R) (imatinib mesylate) is indicated for the treatment of patients with Kit (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). The effectiveness of Gleevec in GIST is based on objective response rate. There are no controlled trials demon
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:7/2/2015)... -- The report "Silage Inoculants & Enzymes ... & Enterococcus), Enzymes (Fibre-digesting & Starch-digesting), Crop-type & Geography ... & Enzymes Market is expected to reach $489.05 Million ... to 2020. Browse 75 market Tables ... P ages and an in-depth TOC on ...
(Date:7/2/2015)... 2015 BGI gab heute bekannt, ... vom American College of Pathologists (CAP) akkreditiert ... erste klinische Next-Generation-Sequencing Labor, das in ... und somit die höchsten Standards an klinischer ... FDA - 21 CFR Part 11 konformen ...
(Date:7/2/2015)... CHICAGO, Ill. , July 2, 2015  AbbVie ... financial results on Friday, July 24, 2015, before the ... webcast of the earnings conference call at 8 a.m. ... through AbbVie,s Investor Relations website at www.abbvieinvestor.com . ... after 11 a.m. Central time. About AbbVie ...
Breaking Medicine Technology:Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 2Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 3Silage Inoculants & Enzymes Market Worth $489.05 Million by 2020 4BGI erhält Akkreditierung vom College of American Pathologists (CAP) 2
... Study Indicates 20-50% Improvement in Post-Preservation,Functional Recovery ... BOTHELL, Wash., June 25, 2007 /PRNewswire-FirstCall/ -- ... marketer of proprietary,hypothermic storage and cryopreservation media ... data from an independent study,of its CryoStor ...
... Also Support Drug's Efficacy at Improving Glycemic ... June 23, 2007 /PRNewswire/ -- VeroScience, LLC,in ... reported today the results of its Phase ... safety of Cycloset(TM) (A,quick release formulation of ...
Cached Medicine Technology:BioLife Solutions Presents Data on CryoStor at International,Society for Cellular Therapy Annual Meeting 2BioLife Solutions Presents Data on CryoStor at International,Society for Cellular Therapy Annual Meeting 3BioLife Solutions Presents Data on CryoStor at International,Society for Cellular Therapy Annual Meeting 4Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 2Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 3Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 4Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 5
(Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... ... for enrollment on July 2nd creating a buzz of media attention. In an ... published online by HonestyFirstReviews.com's Tiffany Hendricks. , "These days many people are feeling ...
(Date:7/3/2015)... , ... July 03, 2015 , ... Renowned rhinoplasty ... dates for the 2016 Dallas Rhinoplasty Symposium . To be held from March ... meeting will be held at the Westin Galleria Dallas. , Designed to take participants ...
(Date:7/3/2015)... ... July 03, 2015 , ... Smoothies are all the rage ... blender and easily accessible, quality ingredients. Aurora Natural is proud to introduce a new ... boost of fiber, protein, antioxidants, vitamins and minerals! , Aurora is offering a variety ...
(Date:7/3/2015)... ... ... " Selfie on a Stick ” was featured on NewsWatch as part ... to consumers. Amanda Forstrom, a technology expert and special reporter for NewsWatch, conducted the ... , Almost every smartphone has an incredibly powerful camera built into it. And when ...
(Date:7/2/2015)... , ... July 02, 2015 , ... sweetFrog Enterprises, LLC. ... The opening is the first sweetFrog store located in Mississippi. The premium frozen yogurt ... in 2014. , The store, located at 104 Railroad Avenue, New Albany, MS 38652, ...
Breaking Medicine News(10 mins):Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 2Health News:High Performance Academy - Review Of Brendon Burchard's New High Performance Training Program Released 3Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Aurora Product, Inc. Announces An Original New Line: Smoothie Fixins’ 2Health News:Learn How to Take Selfies like Kendall Jenner 2Health News:sweetfrog Opens First Location in Mississippi 2
... Remain Stable or Improve in 83% of Patients ... ... Technologies Inc.,(TSX: NDQ), a developer of real-time medical imaging and image ... in Milan, Italy reported independent 12-month follow-up data,on patients treated with ...
... Trademarked Treatment Method Utilizes Novel Team Approach and Variety ... Mind, Body and Spirit Modalities to Treat Individual, ... ), a non-residential treatment and optimal,performance center which specializes ... case study of a client treated with,the Moonview Model, ...
... /Xinhua-PRNewswire-FirstCall/ -- Mindray,Medical International Limited (NYSE: MR ... devices worldwide, today announced the company and,its employees ... million,through the Red Cross Society of China to ... Mr. Xu Hang and Mr. Li Xiting,Mindray,s co-chief ...
... There appears to be,overwhelming support for health care reform ... health care coverage, AARP commissioned a,survey to explore the ... on the,current state of health care in Delaware. The ... their opinions,on prospective state reform., The key survey ...
... May 29 Complementary and alternative,medicine is a ... to be a part of traditional medicine. According ... nearly half of Americans use,complementary and alternative medicine, ... ), "The use of dietary supplements ...
... today new compact,ProSound ultrasound Systems which will be ... Societies for Ultrasound in Medicine and Biology,31st of ... Romania. The ProSound 2 is a,portable diagnostic ultrasound ... image quality technologies developed for,the premium models of ...
Cached Medicine News:Health News:Novadaq Updates on OPTTX Data Reported at Euroretina 2Health News:Novadaq Updates on OPTTX Data Reported at Euroretina 3Health News:Novadaq Updates on OPTTX Data Reported at Euroretina 4Health News:Moonview Sanctuary Releases First Case Study of Client Treated Using Unique Moonview Model 2Health News:Moonview Sanctuary Releases First Case Study of Client Treated Using Unique Moonview Model 3Health News:Moonview Sanctuary Releases First Case Study of Client Treated Using Unique Moonview Model 4Health News:Mindray Donates Cash and Equipment for Sichuan Earthquake Relief 2Health News:AARP Represents the Pulse of Delawareans 50+: Survey Reveals Attitudes about Health Care in Delaware 2Health News:Figure Skater Peggy Fleming Teams With HealthSaver: The Impact of Diet and Supplements on Health 2Health News:Figure Skater Peggy Fleming Teams With HealthSaver: The Impact of Diet and Supplements on Health 3Health News:Figure Skater Peggy Fleming Teams With HealthSaver: The Impact of Diet and Supplements on Health 4Health News:Figure Skater Peggy Fleming Teams With HealthSaver: The Impact of Diet and Supplements on Health 5Health News:Figure Skater Peggy Fleming Teams With HealthSaver: The Impact of Diet and Supplements on Health 6Health News:ALOKA to Unveil a New Compact 'ProSound' Diagnostic Ultrasound System 2
... Professional Diagnostics is a leading provider of ... DFA test menu that includes kits for ... well as miscellaneous conjugates and components. Our ... wide assortment of substrates and kit sizes ...
... Professional Diagnostics is a leading provider of ... DFA test menu that includes kits for ... well as miscellaneous conjugates and components. Our ... wide assortment of substrates and kit sizes ...
... Inverness Medical Professional Diagnostics is a ... extensive IFA and DFA test menu that ... and STDs as well as miscellaneous conjugates ... give you a wide assortment of substrates ...
... Professional Diagnostics is a leading provider of ... DFA test menu that includes kits for ... well as miscellaneous conjugates and components. Our ... wide assortment of substrates and kit sizes ...
Medicine Products: